EORTC

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

Retrieved on: 
Tuesday, January 18, 2022
National Cancer Institute, RCT, Peripheral neuropathy, Patient, Vincristine, Cisplatin, Fibromyalgia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cramp, BLE, Safety, Paclitaxel, CEO, GLOBE, Chronic pain, NCI, Hypoesthesia, Paresthesia, Nerve, Nasdaq, Breakthrough, Pain, Program, Sleep, Company, Quality of life, Diagnosis, Cancer, Food, Risk, Communication, EORTC, Walking, Lists of diseases, FDA, Smartphone, Pharmaceutical industry, Medical device, Medical imaging, Quell, CIPN

Approximately 30% of patients experience chronic CIPN, defined as symptoms lasting longer than 3-6 months after the last chemotherapy treatment.

Key Points: 
  • Approximately 30% of patients experience chronic CIPN, defined as symptoms lasting longer than 3-6 months after the last chemotherapy treatment.
  • There are no FDA approved treatments for CIPN, and those that are used have limited effectiveness and have side effects.
  • Note: The use of Quell for chemotherapy induced peripheral neuropathy is investigational and has not been cleared or approved by the FDA.
  • Quell is a wearable neurostimulation device currently indicated for treatment of lower extremity chronic pain.

Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

Retrieved on: 
Monday, January 10, 2022
Oncology, Medical Supplies, Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, KEYNOTE-091/EORTC-1416-LCG – PEARLS, EORTC, ETOP, Lung Cancer, Merck’s Early-Stage Cancer Clinical Program, Merck, KEYNOTE-091/EORTC-1416-LCG – PEARLS, EORTC, ETOP, LUNG CANCER, MERCK’S EARLY-STAGE CANCER CLINICAL PROGRAM, MERCK

We are encouraged by these results supporting the potential role of KEYTRUDA in stage IB-IIIA non-small cell lung cancer.

Key Points: 
  • We are encouraged by these results supporting the potential role of KEYTRUDA in stage IB-IIIA non-small cell lung cancer.
  • The results from KEYNOTE-091 are a first for KEYTRUDA in the adjuvant treatment setting in patients with stage IB-IIIA NSCLC.
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.
  • Selected KEYTRUDA (pembrolizumab) Indications in the U.S.
    KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

2022 Global Protein Kinase Inhibitors in Oncology Analytical Handbook: Latest Clinical Trial Development & Results - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 5, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Time, ESMO, Tyrosine kinase inhibitor, BIO, AACR, SITC, Environment, Table, Cancer, International, EHA, CMIT, ASH, Scale (analytical tool), EORTC, Biomarker, Business development, ASCO, Microsoft Excel, Industry, Tool, Chemistry (relationship), Medical imaging, Oncology

and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts).

Key Points: 
  • and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts).
  • The Protein Kinase Inhibitors in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia).
  • The Protein Kinase Inhibitors in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.
  • We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials.

2021 Bispecific Molecules in Oncology: Analytical Handbook - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 22, 2021
Pharmaceutical, Health, Oncology, Business development, Microsoft Excel, Decision-making, Tool, Time, Table, Scale (analytical tool), Environment, Industry, EORTC, AACR, BIO, ESMO, EHA, Cancer, SITC, ASCO, International, Chemistry (relationship), Biomarker, CMIT, ASH, Medical imaging

Your Bispecific Molecules in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice.

Key Points: 
  • Your Bispecific Molecules in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice.
  • Your Bispecific Molecules in Oncology: Analytical Tool covers more than 170 companies plus partners who are today developing 484 bispecific drugs where of 411 are in active development in cancer across 177 different targets.
  • The Bispecific Molecules in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia).
  • The Bispecific Molecules in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq

Retrieved on: 
Friday, December 10, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Oncology, Risk, Neoplasm, Population, Patient, Immunotherapy, Pain, ESMO, European Society for Medical Oncology, Phase, TPS, PFS, AES, Safety, Lung cancer, Progression-free survival, Pros, Quality of life, Food, Death, ROG, Lung, Rash, Cancer, Breathe Me, RO, Fatigue, EORTC, Breakthrough therapy, BTD, Esophageal cancer, Hematological Cancer Research Investment and Education Act, Abstract, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hoffmann-La Roche, NE, NSCLC, OS, ITT, Pharmaceutical industry, the CITYSCAPE study1, tiragolumab, lung cancer, Tecentriq® (atezolizumab), Genentech in cancer immunotherapy, Genentech in lung cancer, Genentech, THE CITYSCAPE STUDY1, TIRAGOLUMAB, LUNG CANCER, TECENTRIQ® (ATEZOLIZUMAB), GENENTECH IN CANCER IMMUNOTHERAPY, GENENTECH IN LUNG CANCER, GENENTECH

After 2.5 years median follow-up, tiragolumab plus Tecentriq continued to show an improvement in the intention-to-treat (ITT) population (n=67), driven by the PD-L1-high population (TPS 50%) (n=29).

Key Points: 
  • After 2.5 years median follow-up, tiragolumab plus Tecentriq continued to show an improvement in the intention-to-treat (ITT) population (n=67), driven by the PD-L1-high population (TPS 50%) (n=29).
  • Since 2020, Genentech has initiated five Phase III trials evaluating tiragolumab plus Tecentriq in early and metastatic disease in lung (SKYSCRAPER-01, SKYSCRAPER-02, SKYSCRAPER-03) and esophageal cancers (SKYSCRAPER-07, SKYSCRAPER-08).
  • CITYSCAPE is a global Phase II, randomized and blinded study evaluating tiragolumab plus Tecentriq (atezolizumab) compared with Tecentriq alone in 135 patients with first-line PD-L1-positive locally advanced, unresectable or metastatic non-small cell lung cancer.
  • Patients were randomized 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until progressive disease or loss of clinical benefit.

AmMax Bio Hosting Key Opinion Leader Webinar on AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Retrieved on: 
Tuesday, November 30, 2021
Giant, Patient, Organization, Leiden University Medical Center, Tenosynovial giant cell tumor, Idiopathic pulmonary fibrosis, Cell, Oncology, CSF1, KOL, Sarcoma, Pharmacogenomics, Doctor of Philosophy, National Wilms Tumor Study Group, Advisory Committee on Immunization Practices, Bone tumor, Pain, Quality of life, Research, Risk, Disability, IPF, Adult, Incidence, Health, Infection, Administration, GLOBE, Q&A, Macrophage, GIST, EPOS, Stromal cell, EORTC, Principal investigator, CSF1R, LUMC, Department, Adolescence, Vaccine, Medicine, Medical imaging

REDWOOD CITY, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biotech company developing novel treatments with AMB-05X, its proprietary anti-CSF1R monoclonal antibody platform, today announced that it will host a key opinion leader (KOL) webinar on AMB-05X and its potential as a new standard of care in the treatment of tenosynovial giant cell tumor (TGCT).

Key Points: 
  • Professor Gelderblom has served as a Principal Investigator on multiple clinical trials for tenosynovial giant cell tumor (TGCT) and is currently a key scientific advisor and Investigator to AmMax Bios TGCT clinical development program.
  • Prof. van de Sande has participated in numerous tenosynovial giant cell tumor (TGCT) trials and is a key scientific advisor and Investigator to AmMax Bios TGCT clinical development program.
  • AmMax is enrolling patients in a Phase 2 clinical program for tenosynovial giant cell tumor (TGCT).
  • Based on robust preclinical proof-of-concept results, AmMax is also planning to initiate a Phase 2 clinical study in idiopathic pulmonary fibrosis (IPF).

2021 Conjugated Antibodies in Oncology: Analytical Tool - Identify, Prioritize, and Lead Scientific Assessment of Oncology Opportunities and Competition - ResearchAndMarkets.com

Retrieved on: 
Friday, November 26, 2021
Pharmaceutical, Health, Oncology, Microsoft Excel, International, Scale (analytical tool), Biomarker, Industry, Time, AACR, Cancer, Decision-making, Tool, BIO, ESMO, ASH, ADC, EORTC, EHA, CMIT, Chemistry (relationship), SITC, ASCO, Medical imaging

Your Conjugated Antibodies in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice.

Key Points: 
  • Your Conjugated Antibodies in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice.
  • Your Conjugated Antibodies in Oncology: Analytical Tool covers more than 187 companies plus partners who are today developing 516 ADC drugs where of 390 are in active development in cancer across 153 different targets.
  • The Conjugated Antibodies in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia).
  • The Conjugated Antibodies in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

LIPAC Oncology to Present Two-year Data for Phase 1/2a Study of LiPax at the 22nd Annual Meeting of the Society of Urologic Oncology

Retrieved on: 
Monday, November 15, 2021
Safety, Bladder cancer, EORTC, Nano, Recurrence, Mesothelioma, Society, NMIBC, UTUC, Company, Toxicity, Cancer, Patient, Taxane, Malignant pleural effusion, Medical imaging, Pharmaceutical industry

ET

Key Points: 
  • ET
    LiPax is a precision targeted, locally delivered taxane in Phase 2b development for intravesical instillation in the treatment of non-muscle invasive bladder cancer (NMIBC).
  • LIPAC Oncology completed a Phase 2a clinical trial in August 2020 and intends to initiate a Phase 2b study in the second half of 2021 to further investigate LiPax in the treatment of this condition.
  • LIPAC Oncology is a pharmaceutical company focused on advancing the development of new investigational therapies to treat intracavitary cancers.
  • LiPax, its lead investigational candidate for the treatment of non-muscle invasive bladder cancer, is in Phase 2b development.

Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 9, 2021
Lists of diseases, MIA, MEK, EORTC, Cancer, NRAS, G&A, Therapy, Drug discovery, RAS, U.S. Securities and Exchange Commission, R, MBA, Gene, Research and development, China Bio-Immunity Corporation, KSR, Exercise, Administration, Research, Forward-looking statement, AACR, Risk, Board, Conference, KRAS, GLOBE, Half-life, IPO, RAF, Initial public offering, Chemistry, BRAF, MAPK, Biology, Patient, FDA, General counsel, IND, Pharmaceutical industry, Risk management

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today reported financial results for the third quarter ended September 30, 2021 and provided recent business highlights.

Key Points: 
  • IMM-1-104 Preclinical Data Presented at EORTC 2021: Immuneering presented data from three posters showcasing IMM-1-104 at the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics that took place virtually from October 7-10, 2021.
  • Immuneering also appointed Ann Berman to its board of directors in July 2021.
  • Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2021 were $6.2 million, compared with $4.1 million for the third quarter of 2020.
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2021 were $2.6 million, compared with $0.7 million for the same period of 2020.

Galecto Hosting a Key Opinion Leader Webinar on GB1211: A Potential Treatment For Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, October 28, 2021
EORTC, Prostate Cancer Foundation, NIH, National, Biomarker, Gustave Roussy, IPF, Serum, GLOBE, Doctor of Philosophy, Tumor microenvironment, ASCO, Paris-Saclay University, Providence Portland Medical Center, Research, German Cancer Research Center, International Network to Promote the Rule of Law, European Journal, Jim Valvano, Ruxolitinib, Fibrosis, KOL, Surgical oncology, Idiopathic pulmonary fibrosis, Erasmus University Rotterdam, Full, ECCO, Large-cell lung carcinoma, Lists of people executed in the United States, Editorial board, University Medical Center Utrecht, Q&A, LOXL2, Melanoma, MD, NSCLC, Cancer, Eastern Time Zone, Patient, DKFZ, NASDAQ, Cirrhosis, European Journal of Cancer, Princess, Sarcoma, Board, American Cancer Society, OX40, Prostate cancer, Journal, Pharmaceutical industry

Eggermont, MD, PhD, Princess Mxima Center for Pediatric Oncology; and William L. Redmond, PhD, Providence Portland Medical Center.

Key Points: 
  • Eggermont, MD, PhD, Princess Mxima Center for Pediatric Oncology; and William L. Redmond, PhD, Providence Portland Medical Center.
  • Dr. Eggermont will discuss the current treatment landscape and unmet medical need in treating patients with non-small cell lung cancer (NSCLC).
  • Eggermont, MD, PhD is an internationally recognized expert in surgical oncology, immunotherapy, melanoma, sarcoma and cancer drug development.
  • Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2.